July 14, 2026 · Gastroenterology · DOI: 10.1053/j.gastro.2026.06.024

SOX9-driven SPEM cell lineage plasticity is a potential therapeutic target that mitigates risk of metaplastic progression to gastric cancer

Listen to this summary

The authors investigate the role of SOX9 in the plasticity of spasmolytic polypeptide-expressing metaplastic (SPEM) cells during gastric carcinogenesis, aiming to understand how SOX9 influences metaplasia development and progression to gastric cancer. Their findings reveal that loss of SOX9 in chief cells prevents metaplasia and disrupts the progression of carcinogenesis, highlighting SOX9 as a critical regulator of SPEM cell lineage evolution and a potential therapeutic target to mitigate gastric cancer risk.

Alexis A Guenther, Amanda Ruelas, Brianna Caldwell, Youngwon Cho, Changqing Zhang, Bogun Jang, Benjamin C Duncan, Judith Romero-Gallo, Jonathan T Busada, Richard Peek, Eunyoung Choi

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play